{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:44:25Z","timestamp":1776105865910,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dose reduction of biologics for psoriasis could contribute to more efficient use of these expensive medicines. Evidence on opinions of patients with psoriasis regarding dose reduction is sparse. The objective of this study was therefore to explore patients\u2019 perspectives towards dose reduction of biologics for psoriasis. A qualitative study was conducted, comprising semi-structured interviews with 15 patients with psoriasis with different characteristics and treatment experiences. Interviews were analyzed by inductive thematic analysis. Perceived benefits of biologic dose reduction according to patients were minimizing medication use, lowering risks of adverse effects and lowering societal healthcare costs. Patients reported to have experienced a large impact of their psoriasis, and expressed concerns about loss of disease control due to dose reduction. Fast access to flare treatment and adequate monitoring of disease activity were among reported preconditions. According to patients, they should have confidence in dose reduction effects and should be willing to change their effective treatment. Moreover, addressing information needs and involvement in decision-making were deemed important among patients. In conclusion, addressing patients\u2019 concerns, fulfilling information needs, providing the possibility of resuming standard dose, and involving patients in decision-making are important according to patients with psoriasis when considering biologic dose reduction.<\/jats:p>","DOI":"10.1007\/s00403-023-02566-w","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T02:02:40Z","timestamp":1677117760000},"page":"1735-1745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Patients\u2019 perspectives towards biologic dose reduction in psoriasis: a qualitative study"],"prefix":"10.1007","volume":"315","author":[{"given":"L. S.","family":"van der Schoot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"van Ee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. P. A. H.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H.","family":"Pieterse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M. B.","family":"Seyger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M. G. J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M. P. A.","family":"van den Reek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2566_CR1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Bohannan B, Mburu S, Alarcon I, Kasparek T, Toumi J, Frade S, Barrio SF, Augustin M (2022) Impact of psoriatic disease on quality of life: interim results of a global survey. Dermatol Ther (Heidelb) 12:1055\u20131064. https:\/\/doi.org\/10.1007\/s13555-022-00695-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2566_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M (2020) Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol 156:258\u2013269. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4029","journal-title":"JAMA Dermatol"},{"key":"2566_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4897","author":"S Atalay","year":"2020","unstructured":"Atalay S, van den Reek J, den Broeder AA, van Vugt LJ, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, Koetsier MI, Berends MA, van de Kerkhof PCM, Groenewoud HMM, Kievit W, de Jong E (2020) Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical triAL. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4897","journal-title":"JAMA Dermatol"},{"key":"2566_CR4","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3692","author":"S Atalay","year":"2020","unstructured":"Atalay S, van den Reek J, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, Koetsier MI, Berends MM, van de Kerkhof PCM, Groenewoud HMM, den Broeder AA, de Jong E, Kievit W (2020) Health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the CONDOR study. Acta Derm Venereol. https:\/\/doi.org\/10.2340\/00015555-3692","journal-title":"Acta Derm Venereol"},{"key":"2566_CR5","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3815","author":"S Atalay","year":"2021","unstructured":"Atalay S, van der Schoot LS, Vandermaesen L, van Vugt LJ, Eilander M, van den Reek J, de Jong E (2021) Evaluation of a one-step dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis in daily practice. Acta Derm Venereol. https:\/\/doi.org\/10.2340\/00015555-3815","journal-title":"Acta Derm Venereol"},{"key":"2566_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.annder.2021.07.001","volume":"149","author":"H Aubert","year":"2022","unstructured":"Aubert H, Mah\u00e9 E, Fougerousse AC, Maccari F, Beneton N (2022) Dose spacing and reduction strategies in biotherapies for stable, clear or almost clear psoriasis: a survey of practices in France. Ann Dermatol Venereol 149:68\u201370. https:\/\/doi.org\/10.1016\/j.annder.2021.07.001","journal-title":"Ann Dermatol Venereol"},{"key":"2566_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jid.2020.11.029","volume":"141","author":"A Bazen","year":"2021","unstructured":"Bazen A, Barg FK, Takeshita J (2021) Research techniques made simple: an introduction to qualitative research. J Investig Dermatol 141:241\u2013247. https:\/\/doi.org\/10.1016\/j.jid.2020.11.029","journal-title":"J Investig Dermatol"},{"key":"2566_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3:77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa","journal-title":"Qual Res Psychol"},{"key":"2566_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40271-019-00403-9","volume":"13","author":"SJ Chan","year":"2020","unstructured":"Chan SJ, Stamp LK, Liebergreen N, Ndukwe H, Marra C, Treharne GJ (2020) Tapering biologic therapy for rheumatoid arthritis: a qualitative study of patient perspectives. Patient 13:225\u2013234. https:\/\/doi.org\/10.1007\/s40271-019-00403-9","journal-title":"Patient"},{"key":"2566_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/1468-0009.00206","volume":"79","author":"EB Ferlie","year":"2001","unstructured":"Ferlie EB, Shortell SM (2001) Improving the quality of health care in the United Kingdom and the United States: a framework for change. Milbank Q 79:281\u2013315. https:\/\/doi.org\/10.1111\/1468-0009.00206","journal-title":"Milbank Q"},{"key":"2566_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1748-5908-8-35","volume":"8","author":"SA Flottorp","year":"2013","unstructured":"Flottorp SA, Oxman AD, Krause J, Musila NR, Wensing M, Godycki-Cwirko M, Baker R, Eccles MP (2013) A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. Implement Sci 8:35. https:\/\/doi.org\/10.1186\/1748-5908-8-35","journal-title":"Implement Sci"},{"key":"2566_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/msc.1367","volume":"17","author":"S Hewlett","year":"2019","unstructured":"Hewlett S, Haig-Ferguson A, Rose-Parfitt E, Halls S, Freke S, Creamer P (2019) Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients\u2019 perceptions and needs. Musculoskelet Care 17:63\u201371. https:\/\/doi.org\/10.1002\/msc.1367","journal-title":"Musculoskelet Care"},{"key":"2566_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1001\/jamadermatol.2022.1756","volume":"5","author":"N Hilhorst","year":"2022","unstructured":"Hilhorst N, Deprez E, Pauwels N, Grine L, Lambert J, Hoorens I (2022) Patient-relevant outcomes in psoriasis: a systematic review. JAMA Dermatol 5:5. https:\/\/doi.org\/10.1001\/jamadermatol.2022.1756","journal-title":"JAMA Dermatol"},{"key":"2566_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","volume":"24","author":"AB Kimball","year":"2010","unstructured":"Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M (2010) Psoriasis: is the impairment to a patient\u2019s life cumulative? J Eur Acad Dermatol Venereol 24:989\u20131004. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03705.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2566_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546634.2018.1544408","volume":"31","author":"TA Kouwenhoven","year":"2020","unstructured":"Kouwenhoven TA, van der Ploeg JAM, van de Kerkhof PCM (2020) Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatol Treat 31:13\u201317. https:\/\/doi.org\/10.1080\/09546634.2018.1544408","journal-title":"J Dermatol Treat"},{"key":"2566_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s10067-014-2500-y","volume":"33","author":"IM Markusse","year":"2014","unstructured":"Markusse IM, Akdemir G, Huizinga TW, Allaart CF (2014) Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients\u2019 opinion. Clin Rheumatol 33:1155\u20131159. https:\/\/doi.org\/10.1007\/s10067-014-2500-y","journal-title":"Clin Rheumatol"},{"key":"2566_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01448-z","author":"CAJ Michielsens","year":"2021","unstructured":"Michielsens CAJ, van Muijen ME, Verhoef LM, van den Reek J, de Jong E (2021) Dose tapering of biologics in patients with psoriasis: a scoping review. Drugs. https:\/\/doi.org\/10.1007\/s40265-020-01448-z","journal-title":"Drugs"},{"key":"2566_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/acm.0000000000000388","volume":"89","author":"BC O'Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA (2014) Standards for reporting qualitative research: a synthesis of recommendations. Acad Med 89:1245\u20131251. https:\/\/doi.org\/10.1097\/acm.0000000000000388","journal-title":"Acad Med"},{"key":"2566_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, M\u00fcller-Ladner U, Mysler EF, da Silva JAP, Po\u00f3r G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"2566_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/bjd.18876","volume":"183","author":"B Trettin","year":"2020","unstructured":"Trettin B, Feldman SR, Andersen F, Danbj\u00f8rg DB, Agerskov H (2020) A changed life: the life experiences of patients with psoriasis receiving biological treatment. Br J Dermatol 183:516\u2013523. https:\/\/doi.org\/10.1111\/bjd.18876","journal-title":"Br J Dermatol"},{"key":"2566_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/bjd.13087","volume":"171","author":"JM van den Reek","year":"2014","unstructured":"van den Reek JM, Zweegers J, Kievit W, Otero ME, van Lumig PP, Driessen RJ, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, van de Kerkhof PC, Seyger MM, de Jong EM (2014) \u201cHappy\u201d drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol 171:1189\u20131196. https:\/\/doi.org\/10.1111\/bjd.13087","journal-title":"Br J Dermatol"},{"key":"2566_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-021-02273-4","author":"ME van Muijen","year":"2022","unstructured":"van Muijen ME, van der Schoot LS, van den Reek J, de Jong E (2021) Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide. Arch Dermatol Res. https:\/\/doi.org\/10.1007\/s00403-021-02273-4","journal-title":"Arch Dermatol Res"},{"key":"2566_CR23","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1093\/rheumatology\/key205","volume":"57","author":"LM Verhoef","year":"2018","unstructured":"Verhoef LM, Selten EMH, Vriezekolk JE, de Jong AJL, van den Hoogen FHJ, den Broeder AA, Hulscher ME (2018) The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. Rheumatology (Oxford) 57:1947\u20131955. https:\/\/doi.org\/10.1093\/rheumatology\/key205","journal-title":"Rheumatology (Oxford)"},{"key":"2566_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/03009742.2018.1533034","volume":"48","author":"D Wallis","year":"2019","unstructured":"Wallis D, Holmes C, Holroyd C, Sonpal K, Zarroug J, Adams J, Edwards CJ (2019) Dose reduction of biological therapies for inflammatory rheumatic diseases: what do patients think? Scand J Rheumatol 48:251\u2013252. https:\/\/doi.org\/10.1080\/03009742.2018.1533034","journal-title":"Scand J Rheumatol"},{"issue":"Suppl 1","key":"2566_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.2011.10280.x","volume":"164","author":"RB Warren","year":"2011","unstructured":"Warren RB, Kleyn CE, Gulliver WP (2011) Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 164(Suppl 1):1\u201314. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10280.x","journal-title":"Br J Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02566-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-023-02566-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-023-02566-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T16:08:44Z","timestamp":1689178124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-023-02566-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2566"],"URL":"https:\/\/doi.org\/10.1007\/s00403-023-02566-w","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LS van der Schoot carries out clinical trials for Janssen and Novartis and received speaking fees from Janssen and Eli Lilly. All funding is not personal but goes to the independent Research Fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, The Netherlands. MMB Seyger received grants from\/was involved in clinical trials from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Leo Pharma and Pfizer. She served as a consultant for Abbvie, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer an UCB; fees were paid directly to the institution. EMGJ de Jong has received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands from AbbVie, Pfizer, Novartis, Janssen Pharmaceuticals and Leo Pharma and has acted as consultant and\/or paid speaker for and\/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including AbbVie, Janssen Pharmaceutica, Novartis, Lily, Celgene, Leo Pharma, UCB and Almirall. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands. JMPA van den Reek carries out clinical trials for AbbVie, Celgene and Janssen; has received speaking fees\/attended advisory boards from AbbVie, BMS, Almirall and Janssen and has received reimbursement for attending a symposium from Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands. The other authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Procedures performed in studies involving human participants were in accordance with the ethical standards and applicable laws and regulations including the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The need for ethical approval for the current study was waived by the medical ethical committee Arnhem-Nijmegen (2021-12967). Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval status"}}]}}